SCNI: Scinai Price to Sales

Symbol and logo of brand Scinai (SCNI)

In-house GMP manufacturing minimizes the need for contractors, which supports the price-to-sales multiple. The value 0.20 captures the magnitude of this parameter. The financial stability of Scinai Immunotherapeutics (SCNI) relies on grants and the success of nanobody testing. Patent protection for immunotherapy developments creates growth potential that will be realized upon the completion of clinical trials.

Scinai Immunotherapeutics Ltd. (SCNI): P/S Multiple from 08/18/2024 to 11/17/2026

Metric breakdowns and analytics for Scinai Immunotherapeutics Ltd. (SCNI)

General company analysis:SCNI Scinai Immunotherapeutics Ltd.
Core merchandise of scinai.com

Scinai Immunotherapeutics focuses on developing innovative nano-antibodies to combat autoimmune pathologies and viral infections. By analyzing the current P/S ratio, an investor assesses the company's market value relative to its annual revenue, which helps identify whether the asset is overbought or if its commercial potential is undervalued against the backdrop of expected clinical trial results and the volume of secured grant funding.

Competing companies

argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Price-to-Revenue Coefficient immunome.com (IMNM)|Gossamer Bio Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (KalVista Pharmaceuticals, Inc.)|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharmaceuticals Inc|Market Cap to Revenue SVRA|Market Cap to Revenue Rigel Pharmaceuticals (RIGL)|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene Corp ENGN|Price-to-Revenue Coefficient RAPT Therapeutics, Inc. (RAPT)|Aerovate - P/S Multiple|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|Price to Sales Tiziana Life Sciences Ltd. (TLSA)|Market Cap to Revenue CABA|Ventyx Biosciences (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ELDN (eledon.com)|AGEN - Market Cap to Revenue|CLYM - Price-to-Revenue Ratio|Price-to-Sales Ratio ZURA|ATYR: P/S Multiple|Adagene Corp (ADAG) - P/S Multiple|Market Cap to Revenue IMA|Shattuck Labs, Inc. - Price-to-Sales Ratio|Price-to-Revenue Ratio Equillium Inc (EQ)|P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Revenue Ratio Immunic, Inc. IMUX|P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Revenue Ratio|XFOR: Price-to-Revenue Ratio|ACET: P/S Multiple|CELU - Price-to-Revenue Coefficient|Price-to-Revenue Ratio inmunebio.com|Market Cap to Revenue Ratio BRNS (barinthusbio.com)|P/S Multiple KZR|P/S Multiple SAB Biotherapeutics, Inc (SABS)|P/S Multiple AKTX (Akari Therapeutics, Plc)|P/S Multiple enlivex.com ENLV|QTTB: Market Cap to Revenue|GOVX - P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Revenue Ratio|IBIO - Price-to-Revenue Coefficient|Price-to-Revenue Ratio carismatx.com|XTLB: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Revenue Ratio|Price-to-Revenue Ratio aptevotherapeutics.com APVO|AIM - Market Cap to Revenue|Aditxt - P/S Multiple|Price-to-Revenue Coefficient GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Revenue Ratio|Price to Sales reshapelifesciences.com (HIND)|Price-to-Revenue Ratio Revelation Bio|Price to Sales Indaptus Therapeutics, Inc. INDP|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple